The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.
The International Generic and Biosimilar Medicines Association (IGBA) has launched the first Global Biosimilars Week, an attempt to raise awareness of the value of biosimilars and provide resources for interested persons to find out more about these lower-cost agents
The website for Global Biosimilars Week contains patient testimonials, an introductory overview of biosimilars, and various other resources designed to explain the global reach biosimilars have achieved and their importance for extending treatment options.
“Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support healthcare systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis,” said Hanan Sboul, chair of the IGBA.
IGBA is based in Geneva and is a trade association of companies that develop and market biosimilar medicines, which are often sold at significant discounts to innovator biologics and help to increase access to treatment for patients.
Global Biosimilars Week will continue through Friday, November 20. “Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support health care systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis,” said Erika Satterwhite, chair of the IGBA biosimilars Committee.
The group is inviting interested members of the public to join an online discussion about biosimilars on social media this week using the hashtag #GlobalBiosimilarsWeek.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.